blood pressure

In the clinical tribunal programme ONTARGET®, PROTECTION® and PRoFESS®, over and done with 58,000 patients hold be enrol to explore the cardiovascular protective effects of telmisartan (for more figures make happy look in ewebjema.blogspot.com ).

Telmisartan be discovered and built-up by money matters of Boehringer Ingelheim. Under the trademark Micardis® and MicardisPlus® (combination near hydrochlorothiazide) the guests souk telmisartan contained by 84 country voice the world, plus the USA, Japan and European countries. Telmisartan be market in finding the middle flooring with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in remarkable markets.

Astellas Pharma Inc. co-promotes telmisartan underneath the trademark Micardis®, Bayer HealthCare advance telmisartan under the tear to pieces dub Kinzalmono®, Kinzalkomb® (combination with hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) in markets across Europe. Pritor® and PritorPlus® is also marketed by GlaxoSmithKline in selected markets.

About ONTARGET® The ONTARGET® Trial Programme consists of two randomised, double-blind, multicentre broad-based trial: the vibrations trial, ONTARGET® which have report its grades by the players of 31 March 2008, and a parallel trial TRANSCEND® (Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant subject with cardiovascular Disease), which is tactical to be reported then in the year.6 The renown arsenal in favour of the ONTARGET® Trial be telmisartan 80mg, ramipril 10mg, and finding dream therapy with telmisartan 80mg and ramipril 10mg. In the TRANSCEND® trial the treatment arms be telmisartan 80mg or placebo both on peak of tenet blood anxiety try, not including an ACE or another ARB.6,17 Patients enrolled in The ONTARGET® Trial Programme were aged ≥ 55 years, have a precedent of coronary artery illness, lay a hand on or recent (> 7 days, < I year) transient ischaemic break-in, at a tangent vascular disease, or diabetes mellitus with target-organ impairment such in place of microalbuminuria, ankle-brachial index < 0.8, or departed ventricular hypertrophy.17 The ONTARGET® Trial had a four-fold composite endpoint: — cardiovascular extermination — myocardial infarction — stroke and — hospitalisation for heart close.

cholesterol – read about